Amitriptyline for depression
72 results
1 - 72
Amitriptyline for depression
Amitriptyline for major depression - Antidepressants for treating depression in dementia
- Amitriptyline versus placebo for major depressive disorder: Cochrane systematic review
- Pharmacological treatment of depression
- Chronic pain
- Antidepressants for depression in Parkinson's disease
- Amitriptyline for neuropathic pain in adults
Amitriptyline effect on QOL in teens with IBS is equivocal- Amitriptyline for fibromyalgia in adults
- SR: Limited evidence suggests no effective treatments for central poststroke pain
- Therapies for depression in Parkinson's disease: Cochrane systematic review
- Antipsychotics for fibromyalgia in adults
- Antidepressants for pain management in adults with chronic pain: a network meta‐analysis
- Antidepressants for neuropathic pain: Cochrane systematic review
- Antidepressants for co-occurring depression and alcohol dependence
- Antidepressants for patients with tinnitus: Cochrane systematic review
- Antiepileptic drugs for chronic non‐cancer pain in children and adolescents
- Nortriptyline for neuropathic pain in adults
- Paroxetine versus other anti-depressive agents for depression
- Fluvoxamine versus other anti‐depressive agents for depression
- Tricyclic drugs for depression in children and adolescents
- Psychosocial support for patients with cancer
- Antidepressants for chronic non‐cancer pain in children and adolescents
- Are some antidepressants safer than others regarding suicide risk?
- Sertraline versus other antidepressive agents for depression
- Fluoxetine versus other types of pharmacotherapy for depression
- Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults
- Antidepressants for the treatment of people with co-occurring depression and alcohol dependence: Cochrane systematic review
- Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs): Cochrane systematic review
- Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension‐type headache in adults
- Chronic prostatitis
- Desipramine for neuropathic pain in adults
- Imipramine for neuropathic pain in adults
- Pharmacologic interventions for treating phantom limb pain
- Continued prescription of antidepressant drugs for relapse prevention in depression
- Venlafaxine in the treatment of neuropathic pain
- Cannabinoids for fibromyalgia
- Topical lidocaine for neuropathic pain in adults
- Antidepressants for anorexia nervosa
- aDrugs commonly causing poisonings
- Nonopioids equivalent to opioids for severe chronic back, hip, or knee pain with fewer adverse outcomes
- Acute stress reaction and post-traumatic stress disorder
- Fluoxetine versus other types of pharmacotherapy for depression
- Antidepressants for insomnia in adults: Cochrane systematic review
- Paroxetine versus other anti‐depressive agents for depression
- Mirtazapine for fibromyalgia in adults
- Chronic diseases and pregnancy
- Anticonvulsants for fibromyalgia: Cochrane systematic review
- Migraine
- Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
- Antidepressants versus placebo for people with bulimia nervosa
- Antidepressants for functional abdominal pain disorders in children and adolescents
- Multiple sclerosis (MS)
- Functional bowel disorders and the irritable bowel syndrome (IBS)
- Cognitive behavioural therapies for fibromyalgia
- Use of medication during pregnancy